User menu

Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.

Bibliographic reference Temmerman, F ; Gevers, T ; Ho, Thien Anh ; Vanslembrouck, R ; Coudyzer, W ; et. al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.. In: Alimentary pharmacology & therapeutics, Vol. 38, no. 4, p. 397-406 (2013)
Permanent URL
  1. Temmerman F., Missiaen L., Bammens B., Laleman W., Cassiman D., Verslype C., van Pelt J., Nevens F., Systematic review: the pathophysiology and management of polycystic liver disease : Systematic review: pathophysiology and management of polycystic liver disease, 10.1111/j.1365-2036.2011.04783.x
  2. Bae K. T., Magnetic Resonance Imaging Evaluation of Hepatic Cysts in Early Autosomal-Dominant Polycystic Kidney Disease: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Cohort, 10.2215/cjn.00080605
  3. Hoevenaren Inge A., Wester Ruth, Schrier Robert W., McFann Kim, Doctor R. Brian, Drenth Joost P. H., Everson Gregory T., Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease : Clinical forms of polycystic liver, 10.1111/j.1478-3231.2007.01595.x
  4. Van Keimpema Loes, De Koning Daan B., Van Hoek Bart, Van Den Berg Aad P., Van Oijen Martijn G. H., De Man Robert A., Nevens Frederik, Drenth Joost P. H., Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases : Clinical characterization of PCLD, 10.1111/j.1478-3231.2010.02247.x
  5. Schnelldorfer Thomas, Torres Vicente E., Zakaria Shaheen, Rosen Charles B., Nagorney David M., Polycystic Liver Disease : A Critical Appraisal of Hepatic Resection, Cyst Fenestration, and Liver Transplantation, 10.1097/sla.0b013e3181ad83dc
  6. Pirenne Jacques, Aerts Raymond, Yoong Kim, Gunson Bridget, Koshiba Takaaki, Fourneau Inge, Mayer David, Buckels John, Mirza Darius, Roskams Tania, Elias Elwin, Nevens Frederik, Fevery Johan, McMaster Paul, Liver transplantation for polycystic liver disease, 10.1053/jlts.2001.22178
  7. van Keimpema Loes, Nevens Frederik, Adam René, Porte Robert J., Fikatas Panagiotis, Becker Thomas, Kirkegaard Preben, Metselaar Herold J., Drenth Joost P. H., , Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study : Liver transplantation for polycystic livers, 10.1111/j.1432-2277.2011.01360.x
  8. Masyuk Tatyana V., Masyuk Anatoliy I., Torres Vicente E., Harris Peter C., Larusso Nicholas F., Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3′,5′-Cyclic Monophosphate, 10.1053/j.gastro.2006.12.039
  9. van Keimpema Loes, Nevens Frederik, Vanslembrouck Ragna, van Oijen Martijn G.H., Hoffmann Aswin L., Dekker Helena M., de Man Robert A., Drenth Joost P.H., Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial, 10.1053/j.gastro.2009.07.052
  10. Hogan M. C., Masyuk T. V., Page L. J., Kubly V. J., Bergstralh E. J., Li X., Kim B., King B. F., Glockner J., Holmes D. R., Rossetti S., Harris P. C., LaRusso N. F., Torres V. E., Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease, 10.1681/asn.2009121291
  11. Ruggenenti Piero, Remuzzi Andrea, Ondei Patrizia, Fasolini Giorgio, Antiga Luca, Ene-Iordache Bogdan, Remuzzi Giuseppe, Epstein Franklin H., Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease, 10.1111/j.1523-1755.2005.00395.x
  12. Caroli A., Antiga L., Cafaro M., Fasolini G., Remuzzi A., Remuzzi G., Ruggenenti P., Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide, 10.2215/cjn.05380709
  13. Khan M. S., El-Khouly F., Davies P., Toumpanakis C., Caplin M. E., Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) : Prolonged release Lanreotide in carcinoid syndrome, 10.1111/j.1365-2036.2011.04693.x
  14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 (2006)
  15. Kilbride Hannah S., Stevens Paul E., Eaglestone Gillian, Knight Sarah, Carter Joanne L., Delaney Michael P., Farmer Christopher K.T., Irving Jean, O'Riordan Shelagh E., Dalton R. Neil, Lamb Edmund J., Accuracy of the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (CKD Epidemiology Collaboration) Equations for Estimation of GFR in the Elderly, 10.1053/j.ajkd.2012.06.016
  16. Hogan M. C., Masyuk T. V., Page L., Holmes D. R., Li X., Bergstralh E. J., Irazabal M. V., Kim B., King B. F., Glockner J. F., LaRusso N. F., Torres V. E., Somatostatin analog therapy for severe polycystic liver disease: results after 2 years, 10.1093/ndt/gfs152
  17. Chrispijn M., Nevens F., Gevers T. J. G., Vanslembrouck R., van Oijen M. G. H., Coudyzer W., Hoffmann A. L., Dekker H. M., de Man R. A., van Keimpema L., Drenth J. P. H., The long-term outcome of patients with polycystic liver disease treated with lanreotide : Long-term lanreotide in polycystic liver patients, 10.1111/j.1365-2036.2011.04923.x
  18. Schmidt Alice, Pleiner Johannes, Schaller Georg, Roden Michael, Dallinger Susanne, Mayer Gert, Schmetterer Leopold, Wolzt Michael, Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release, 10.1046/j.1523-1755.2002.00320.x
  19. Chapman A. B., Bost J. E., Torres V. E., Guay-Woodford L., Bae K. T., Landsittel D., Li J., King B. F., Martin D., Wetzel L. H., Lockhart M. E., Harris P. C., Moxey-Mims M., Flessner M., Bennett W. M., Grantham J. J., Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease, 10.2215/cjn.09500911
  20. Andries Magdalene, Glintborg Dorte, Kvistborg Annette, Hagen Claus, Andersen Marianne, A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly : Lanreotide Autogel treatment in acromegaly, 10.1111/j.1365-2265.2007.03067.x
  21. Martino Maria Cristina De, Hofland Leo J., Lamberts Steven W.J., Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications, Neuroendocrinology - Pathological Situations and Diseases (2010) ISBN:9780444536167 p.255-280, 10.1016/s0079-6123(10)82011-4